Rebel’s Edge Notes

The Treasury Department said Wednesday it will at least double the level of government debt buybacks in the next few months, targeting the sensitive longer-duration segment of the market. Yields tumbled following the announcement and stock market futures surged.

Prediction: Fed Decision 

MRNA +106.0%, MRK +8.5%: Phase 3 personalized mRNA melanoma vaccine + Keytruda met the primary recurrence-free-survival endpoint and key metastasis endpoint; first positive late-stage result for an individualized mRNA cancer vaccine. GOVX +18.5%, BNTX +15.0% (vaccine/oncology sympathy). MRNA is the Nasdaq ticker for Moderna, Inc., a biotechnology company specializing in messenger RNA (mRNA) medicines, best known for its COVID-19 vaccine Spikevax and now expanding into other vaccines and oncology. On August 19, 2026, the stock surged dramatically (roughly doubling, up 90–100%+ in early trading) after Moderna and partner Merck announced positive interim results from a large Phase 3 trial of their personalized mRNA cancer vaccine (intismeran autogene / V940 / mRNA-4157) combined with Merck’s Keytruda. The study, involving over 1,100 high-risk patients with stage IIB–IV melanoma whose tumors had been surgically removed, met its primary endpoint of improved recurrence-free survival and a key secondary endpoint of distant metastasis-free survival compared with Keytruda alone

EL +14%: Q4 EPS $0.39 vs $0.32 expected and revenue $3.63B vs $3.55B; FY profit outlook came in above Street expectations. The Estée Lauder Companies (NYSE: EL) is a major prestige beauty and cosmetics firm known for brands like Estée Lauder, Clinique, La Mer, MAC, Jo Malone, and The Ordinary. On August 19, 2026, its shares surged (up roughly 8–13% in premarket trading) after the company reported fiscal 2026 fourth-quarter and full-year results that beat Wall Street estimates, signaling that its multi-year turnaround is gaining traction. Q4 revenue rose 6% to about $3.63 billion (organic sales +5%), with adjusted EPS of $0.39 topping the ~$0.32 consensus, while full-year net sales increased 5% to roughly $15.05 billion (organic +3%) and adjusted EPS climbed to $2.51 from $1.51 the prior year.

NBIS: Nebius Group is trading lower today (down 12%) primarily because the AI cloud company announced a proposed private offering of $4.5 billion in convertible senior notes ($2.75 billion due 2030 and $1.75 billion due 2034, with an option for up to an additional $675 million). The proceeds are earmarked for data-center construction, AI cloud expansion, and purchases of components such as GPUs to support rapid growth in AI infrastructure demand. While the financing provides substantial capital for scaling, investors are reacting to the potential dilution risk if the notes convert into shares, along with added debt obligations and broader sector concerns about heavy capital spending in the “neocloud” space—this comes after a strong recent run driven by explosive Q2 revenue growth (over 450% year-over-year).

Coherent (COHR), CoreWeave (CRWV), and Lumentum (LITE) are optical and AI-infrastructure plays that have seen sharp recent volatility. COHR and LITE delivered strong fiscal Q4 results driven by AI datacenter demand for optical transceivers and modules, with COHR posting record revenue and raised guidance while LITE showed surging sales, expanding margins (gross near 50%), and solid Q1 outlook; both then sold off sharply on profit-taking and broader tech weakness. CRWV, a major AI cloud/GPU infrastructure provider, has a large backlog (reported in the $100B+ range in recent updates) and positive analyst targets, but the shares also dropped hard amid sector pressure and elevated volatility.